179 related articles for article (PubMed ID: 21692065)
1. Pilot study of duloxetine for treatment of aromatase inhibitor-associated musculoskeletal symptoms.
Henry NL; Banerjee M; Wicha M; Van Poznak C; Smerage JB; Schott AF; Griggs JJ; Hayes DF
Cancer; 2011 Dec; 117(24):5469-75. PubMed ID: 21692065
[TBL] [Abstract][Full Text] [Related]
2. Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202.
Henry NL; Unger JM; Schott AF; Fehrenbacher L; Flynn PJ; Prow DM; Sharer CW; Burton GV; Kuzma CS; Moseley A; Lew DL; Fisch MJ; Moinpour CM; Hershman DL; Wade JL
J Clin Oncol; 2018 Feb; 36(4):326-332. PubMed ID: 29136387
[TBL] [Abstract][Full Text] [Related]
3. Treatment of depression and menopause-related symptoms with the serotonin-norepinephrine reuptake inhibitor duloxetine.
Joffe H; Soares CN; Petrillo LF; Viguera AC; Somley BL; Koch JK; Cohen LS
J Clin Psychiatry; 2007 Jun; 68(6):943-50. PubMed ID: 17592922
[TBL] [Abstract][Full Text] [Related]
4. Association between body mass index and response to duloxetine for aromatase inhibitor-associated musculoskeletal symptoms in SWOG S1202.
Henry NL; Unger JM; Till C; Schott AF; Crew KD; Lew DL; Fisch MJ; Moinpour CM; Wade JL; Hershman DL
Cancer; 2019 Jun; 125(12):2123-2129. PubMed ID: 30861098
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of duloxetine in patients with chronic low back pain.
Skljarevski V; Desaiah D; Liu-Seifert H; Zhang Q; Chappell AS; Detke MJ; Iyengar S; Atkinson JH; Backonja M
Spine (Phila Pa 1976); 2010 Jun; 35(13):E578-85. PubMed ID: 20461028
[TBL] [Abstract][Full Text] [Related]
6. Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder.
Brannan SK; Mallinckrodt CH; Brown EB; Wohlreich MM; Watkin JG; Schatzberg AF
J Psychiatr Res; 2005 Jan; 39(1):43-53. PubMed ID: 15504423
[TBL] [Abstract][Full Text] [Related]
7. Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia syndrome.
Häuser W; Urrútia G; Tort S; Uçeyler N; Walitt B
Cochrane Database Syst Rev; 2013 Jan; (1):CD010292. PubMed ID: 23440848
[TBL] [Abstract][Full Text] [Related]
8. Duloxetine: a review of its use in the treatment of generalized anxiety disorder.
Carter NJ; McCormack PL
CNS Drugs; 2009; 23(6):523-41. PubMed ID: 19480470
[TBL] [Abstract][Full Text] [Related]
9. Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia.
Welsch P; Üçeyler N; Klose P; Walitt B; Häuser W
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD010292. PubMed ID: 29489029
[TBL] [Abstract][Full Text] [Related]
10. Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study.
Nierenberg AA; Greist JH; Mallinckrodt CH; Prakash A; Sambunaris A; Tollefson GD; Wohlreich MM
Curr Med Res Opin; 2007 Feb; 23(2):401-16. PubMed ID: 17288694
[TBL] [Abstract][Full Text] [Related]
11. Attributes of response in depressed patients switched to treatment with duloxetine.
Sagman D; McIntosh D; Lee MS; Li H; Ruschel S; Hussain N; Granger RE; Lee AC; Raskin J
Int J Clin Pract; 2011 Jan; 65(1):73-81. PubMed ID: 21078010
[TBL] [Abstract][Full Text] [Related]
12. Single arm phase II study of oral vitamin B12 for the treatment of musculoskeletal symptoms associated with aromatase inhibitors in women with early stage breast cancer.
Campbell A; Heydarian R; Ochoa C; Dwivedi AK; Nahleh ZA
Breast J; 2018 May; 24(3):260-268. PubMed ID: 29442401
[TBL] [Abstract][Full Text] [Related]
13. Duloxetine for the treatment of major depressive disorder in older patients.
Nelson JC; Wohlreich MM; Mallinckrodt CH; Detke MJ; Watkin JG; Kennedy JS
Am J Geriatr Psychiatry; 2005 Mar; 13(3):227-35. PubMed ID: 15728754
[TBL] [Abstract][Full Text] [Related]
14. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial.
Smith EM; Pang H; Cirrincione C; Fleishman S; Paskett ED; Ahles T; Bressler LR; Fadul CE; Knox C; Le-Lindqwister N; Gilman PB; Shapiro CL;
JAMA; 2013 Apr; 309(13):1359-67. PubMed ID: 23549581
[TBL] [Abstract][Full Text] [Related]
15. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain.
Wernicke JF; Pritchett YL; D'Souza DN; Waninger A; Tran P; Iyengar S; Raskin J
Neurology; 2006 Oct; 67(8):1411-20. PubMed ID: 17060567
[TBL] [Abstract][Full Text] [Related]
16. Flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial.
Arnold LM; Clauw D; Wang F; Ahl J; Gaynor PJ; Wohlreich MM
J Rheumatol; 2010 Dec; 37(12):2578-86. PubMed ID: 20843911
[TBL] [Abstract][Full Text] [Related]
17. Duloxetine in the treatment of major depressive disorder: an open-label study.
Hudson JI; Perahia DG; Gilaberte I; Wang F; Watkin JG; Detke MJ
BMC Psychiatry; 2007 Aug; 7():43. PubMed ID: 17725843
[TBL] [Abstract][Full Text] [Related]
18. Duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial.
Skljarevski V; Zhang S; Desaiah D; Alaka KJ; Palacios S; Miazgowski T; Patrick K
J Pain; 2010 Dec; 11(12):1282-90. PubMed ID: 20472510
[TBL] [Abstract][Full Text] [Related]
19. Duloxetine is effective in treating depression in multiple sclerosis patients: an open-label multicenter study.
Solaro C; Bergamaschi R; Rezzani C; Mueller M; Trabucco E; Bargiggia V; Dematteis F; Mattioda A; Cimino V; Restivo D; Patti F; Cavalla P
Clin Neuropharmacol; 2013; 36(4):114-6. PubMed ID: 23783007
[TBL] [Abstract][Full Text] [Related]
20. A systematic review of duloxetine for osteoarthritic pain: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed?
Citrome L; Weiss-Citrome A
Postgrad Med; 2012 Jan; 124(1):83-93. PubMed ID: 22314118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
